Stephan Mueller1,2, Ephraim B Winzer3, André Duvinage1,2, Andreas B Gevaert4,5, Frank Edelmann6,7, Bernhard Haller8, Elisabeth Pieske-Kraigher6,7, Paul Beckers4,5, Anna Bobenko6,7, Jennifer Hommel3, Caroline M Van de Heyning4,5, Katrin Esefeld1,2, Pia von Korn1,2, Jeffrey W Christle1,9, Mark J Haykowsky10, Axel Linke3, Ulrik Wisløff11, Volker Adams3, Burkert Pieske6,7, Emeline M van Craenenbroeck4,5, Martin Halle1,2. 1. Department of Prevention and Sports Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, Munich, Germany. 2. DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany. 3. Heart Center Dresden-University Hospital, Department of Internal Medicine and Cardiology, Technische Universität Dresden, Dresden, Germany. 4. Research Group Cardiovascular Diseases, GENCOR Department, University of Antwerp, Antwerp, Belgium. 5. Department of Cardiology, Antwerp University Hospital, Edegem, Belgium. 6. Department of Internal Medicine and Cardiology, Campus Virchow Klinikum, Charité Universitätsmedizin Berlin, Berlin, Germany. 7. DZHK (German Center for Cardiovascular Research), partner site Berlin, Berlin, Germany. 8. Institute of Medical Informatics, Statistics and Epidemiology, Technical University of Munich, Munich, Germany. 9. Department of Medicine, Division of Cardiovascular Medicine, Stanford University, Stanford, California. 10. Faculty of Nursing, University of Alberta, Edmonton, Alberta, Canada. 11. The Cardiac Exercise Research Group at Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway.
Abstract
Importance: Endurance exercise is effective in improving peak oxygen consumption (peak V̇o2) in patients with heart failure with preserved ejection fraction (HFpEF). However, it remains unknown whether differing modes of exercise have different effects. Objective: To determine whether high-intensity interval training, moderate continuous training, and guideline-based advice on physical activity have different effects on change in peak V̇o2 in patients with HFpEF. Design, Setting, and Participants: Randomized clinical trial at 5 sites (Berlin, Leipzig, and Munich, Germany; Antwerp, Belgium; and Trondheim, Norway) from July 2014 to September 2018. From 532 screened patients, 180 sedentary patients with chronic, stable HFpEF were enrolled. Outcomes were analyzed by core laboratories blinded to treatment groups; however, the patients and staff conducting the evaluations were not blinded. Interventions: Patients were randomly assigned (1:1:1; n = 60 per group) to high-intensity interval training (3 × 38 minutes/week), moderate continuous training (5 × 40 minutes/week), or guideline control (1-time advice on physical activity according to guidelines) for 12 months (3 months in clinic followed by 9 months telemedically supervised home-based exercise). Main Outcomes and Measures: Primary end point was change in peak V̇o2 after 3 months, with the minimal clinically important difference set at 2.5 mL/kg/min. Secondary end points included changes in metrics of cardiorespiratory fitness, diastolic function, and natriuretic peptides after 3 and 12 months. Results: Among 180 patients who were randomized (mean age, 70 years; 120 women [67%]), 166 (92%) and 154 (86%) completed evaluation at 3 and 12 months, respectively. Change in peak V̇o2 over 3 months for high-intensity interval training vs guideline control was 1.1 vs -0.6 mL/kg/min (difference, 1.5 [95% CI, 0.4 to 2.7]); for moderate continuous training vs guideline control, 1.6 vs -0.6 mL/kg/min (difference, 2.0 [95% CI, 0.9 to 3.1]); and for high-intensity interval training vs moderate continuous training, 1.1 vs 1.6 mL/kg/min (difference, -0.4 [95% CI, -1.4 to 0.6]). No comparisons were statistically significant after 12 months. There were no significant changes in diastolic function or natriuretic peptides. Acute coronary syndrome was recorded in 4 high-intensity interval training patients (7%), 3 moderate continuous training patients (5%), and 5 guideline control patients (8%). Conclusions and Relevance: Among patients with HFpEF, there was no statistically significant difference in change in peak V̇o2 at 3 months between those assigned to high-intensity interval vs moderate continuous training, and neither group met the prespecified minimal clinically important difference compared with the guideline control. These findings do not support either high-intensity interval training or moderate continuous training compared with guideline-based physical activity for patients with HFpEF. Trial Registration: ClinicalTrials.gov Identifier: NCT02078947.
RCT Entities:
Importance: Endurance exercise is effective in improving peak oxygen consumption (peak V̇o2) in patients with heart failure with preserved ejection fraction (HFpEF). However, it remains unknown whether differing modes of exercise have different effects. Objective: To determine whether high-intensity interval training, moderate continuous training, and guideline-based advice on physical activity have different effects on change in peak V̇o2 in patients with HFpEF. Design, Setting, and Participants: Randomized clinical trial at 5 sites (Berlin, Leipzig, and Munich, Germany; Antwerp, Belgium; and Trondheim, Norway) from July 2014 to September 2018. From 532 screened patients, 180 sedentary patients with chronic, stable HFpEF were enrolled. Outcomes were analyzed by core laboratories blinded to treatment groups; however, the patients and staff conducting the evaluations were not blinded. Interventions: Patients were randomly assigned (1:1:1; n = 60 per group) to high-intensity interval training (3 × 38 minutes/week), moderate continuous training (5 × 40 minutes/week), or guideline control (1-time advice on physical activity according to guidelines) for 12 months (3 months in clinic followed by 9 months telemedically supervised home-based exercise). Main Outcomes and Measures: Primary end point was change in peak V̇o2 after 3 months, with the minimal clinically important difference set at 2.5 mL/kg/min. Secondary end points included changes in metrics of cardiorespiratory fitness, diastolic function, and natriuretic peptides after 3 and 12 months. Results: Among 180 patients who were randomized (mean age, 70 years; 120 women [67%]), 166 (92%) and 154 (86%) completed evaluation at 3 and 12 months, respectively. Change in peak V̇o2 over 3 months for high-intensity interval training vs guideline control was 1.1 vs -0.6 mL/kg/min (difference, 1.5 [95% CI, 0.4 to 2.7]); for moderate continuous training vs guideline control, 1.6 vs -0.6 mL/kg/min (difference, 2.0 [95% CI, 0.9 to 3.1]); and for high-intensity interval training vs moderate continuous training, 1.1 vs 1.6 mL/kg/min (difference, -0.4 [95% CI, -1.4 to 0.6]). No comparisons were statistically significant after 12 months. There were no significant changes in diastolic function or natriuretic peptides. Acute coronary syndrome was recorded in 4 high-intensity interval training patients (7%), 3 moderate continuous training patients (5%), and 5 guideline control patients (8%). Conclusions and Relevance: Among patients with HFpEF, there was no statistically significant difference in change in peak V̇o2 at 3 months between those assigned to high-intensity interval vs moderate continuous training, and neither group met the prespecified minimal clinically important difference compared with the guideline control. These findings do not support either high-intensity interval training or moderate continuous training compared with guideline-based physical activity for patients with HFpEF. Trial Registration: ClinicalTrials.gov Identifier: NCT02078947.
Authors: Alberto Jorge Alves; Fernando Ribeiro; Ehud Goldhammer; Yelena Rivlin; Uri Rosenschein; João Luís Viana; José Alberto Duarte; Michael Sagiv; José Oliveira Journal: Med Sci Sports Exerc Date: 2012-05 Impact factor: 5.411
Authors: Wesley J Tucker; Michael D Nelson; Rhys I Beaudry; Martin Halle; Satyam Sarma; Dalane W Kitzman; Andre La Gerche; Mark J Haykowksy Journal: Card Fail Rev Date: 2016-11
Authors: Dalane W Kitzman; Peter H Brubaker; Timothy M Morgan; Kathryn P Stewart; William C Little Journal: Circ Heart Fail Date: 2010-09-17 Impact factor: 8.790
Authors: Dalane W Kitzman; Peter Brubaker; Timothy Morgan; Mark Haykowsky; Gregory Hundley; William E Kraus; Joel Eggebeen; Barbara J Nicklas Journal: JAMA Date: 2016-01-05 Impact factor: 56.272
Authors: Scott D Solomon; John J V McMurray; Inder S Anand; Junbo Ge; Carolyn S P Lam; Aldo P Maggioni; Felipe Martinez; Milton Packer; Marc A Pfeffer; Burkert Pieske; Margaret M Redfield; Jean L Rouleau; Dirk J van Veldhuisen; Faiez Zannad; Michael R Zile; Akshay S Desai; Brian Claggett; Pardeep S Jhund; Sergey A Boytsov; Josep Comin-Colet; John Cleland; Hans-Dirk Düngen; Eva Goncalvesova; Tzvetana Katova; Jose F Kerr Saraiva; Małgorzata Lelonek; Bela Merkely; Michele Senni; Sanjiv J Shah; Jingmin Zhou; Adel R Rizkala; Jianjian Gong; Victor C Shi; Martin P Lefkowitz Journal: N Engl J Med Date: 2019-09-01 Impact factor: 91.245
Authors: Anderson Donelli da Silveira; Juliana Beust de Lima; Diogo da Silva Piardi; Débora Dos Santos Macedo; Maurice Zanini; Rosane Nery; Jari A Laukkanen; Ricardo Stein Journal: Eur J Prev Cardiol Date: 2020-01-21 Impact factor: 7.804
Authors: Lisa N Yelland; Thomas R Sullivan; Merryn Voysey; Katherine J Lee; Jonathan A Cook; Andrew B Forbes Journal: Clin Trials Date: 2015-06-01 Impact factor: 2.486
Authors: Øyvind Ellingsen; Martin Halle; Viviane Conraads; Asbjørn Støylen; Håvard Dalen; Charles Delagardelle; Alf-Inge Larsen; Torstein Hole; Alessandro Mezzani; Emeline M Van Craenenbroeck; Vibeke Videm; Paul Beckers; Jeffrey W Christle; Ephraim Winzer; Norman Mangner; Felix Woitek; Robert Höllriegel; Axel Pressler; Tea Monk-Hansen; Martin Snoer; Patrick Feiereisen; Torstein Valborgland; John Kjekshus; Rainer Hambrecht; Stephan Gielen; Trine Karlsen; Eva Prescott; Axel Linke Journal: Circulation Date: 2017-01-12 Impact factor: 29.690
Authors: Windy W Alonso; Kevin A Kupzyk; Joseph F Norman; Scott W Lundgren; Alfred Fisher; Merry L Lindsey; Steven J Keteyian; Bunny J Pozehl Journal: J Card Fail Date: 2021-09-15 Impact factor: 5.712
Authors: Ambarish Pandey; Sanjiv J Shah; Javed Butler; Dean L Kellogg; Gregory D Lewis; Daniel E Forman; Robert J Mentz; Barry A Borlaug; Marc A Simon; Julio A Chirinos; Roger A Fielding; Elena Volpi; Anthony J A Molina; Mark J Haykowsky; Flora Sam; Bret H Goodpaster; Alain G Bertoni; Jamie N Justice; James P White; Jingzhone Ding; Scott L Hummel; Nathan K LeBrasseur; George E Taffet; Iraklis I Pipinos; Dalane Kitzman Journal: J Am Coll Cardiol Date: 2021-09-14 Impact factor: 27.203
Authors: Eduardo M Vilela; Ricardo Ladeiras-Lopes; Ana Joao; Joana Braga; Susana Torres; Sofia Viamonte; José Ribeiro; Madalena Teixeira; José P Nunes; Ricardo Fontes-Carvalho Journal: World J Cardiol Date: 2021-12-26